By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted ...

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...

Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...

WASHINGTON -- Pfizer announced Friday that it submitted a request to the U.S. Food and Drug Administration to allow emergency use of its COVID-19 vaccine to children as young as 12. This is the next ...